Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 283 articles:
HTML format



Single Articles


    July 2024

  1. Erratum: The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
    Hepatology. 2024;80:E22.
    PubMed    



  2. Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    PubMed    


    June 2024
  3. LI J, Ma X, Xuan Q, Li Q, et al
    Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972.
    PubMed     Abstract available


  4. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    PubMed    


  5. BITTERMANN T, Yagan L, Kathawate RG, Weinberg EM, et al
    Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis.
    Hepatology. 2024 Jun 12. doi: 10.1097/HEP.0000000000000961.
    PubMed     Abstract available


  6. TANG T, Li LQ, Wang ZD
    Baseline viral load in chronic hepatitis B may be clinically significant but must be interpreted with caution.
    Hepatology. 2024 Jun 6. doi: 10.1097/HEP.0000000000000956.
    PubMed    


  7. CORNBERG M, Wedemeyer H
    Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
    Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
    PubMed    


  8. HOWELL J, Hellard ME
    Reply: Provider preparedness for functional cure of chronic hepatitis B.
    Hepatology. 2024;79:E160.
    PubMed    


    May 2024
  9. FENG Z
    Cathepsins prime hepatitis E virus for cell entry.
    Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000936.
    PubMed    


  10. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    PubMed     Abstract available


  11. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    PubMed    


  12. LUO C
    Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000928.
    PubMed    


  13. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    PubMed     Abstract available


  14. KLOHN M, Burkard T, Janzen J, Haase JA, et al
    Targeting cellular cathepsins inhibits hepatitis E virus entry.
    Hepatology. 2024 May 10. doi: 10.1097/HEP.0000000000000912.
    PubMed     Abstract available


  15. SHENOY A, Fontana RJ
    HDV screening in chronic HBV: An unmet need of growing importance.
    Hepatology. 2024;79:979-982.
    PubMed    


  16. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    PubMed    


    April 2024
  17. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    PubMed     Abstract available


  18. ZAHOOR MA, Feld JB, Lin HS, Mosa AI, et al
    Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN trials.
    Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000878.
    PubMed     Abstract available


  19. DUNN W, Li Y, Singal AK, Simonetto DA, et al
    An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000883.
    PubMed     Abstract available


  20. CHOI WM, Lim YS
    "Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients".
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000884.
    PubMed    


  21. HE T, Zhang D
    Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000882.
    PubMed    


    March 2024
  22. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    PubMed     Abstract available


  23. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    PubMed     Abstract available


  24. PERRILLO RP, Janssen HLA
    Letter to the Editor: Provider preparedness for functional cure of chronic hepatitis B.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000810.
    PubMed    


  25. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    PubMed    


  26. GRATACOS-GINES J, Ruz-Zafra P, Celada-Sendino M, Marti-Carretero A, et al
    Recurrent alcohol-associated hepatitis is common and is associated with increased mortality.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000825.
    PubMed     Abstract available


    February 2024
  27. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed     Abstract available


  28. YAMAZAKI T, Kouno T, Hsu CL, Hartmann P, et al
    Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000777.
    PubMed     Abstract available


  29. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    PubMed    


  30. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    PubMed    


  31. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    PubMed    


  32. DIMOU A, Zachou K, Kostara C, Azariadis K, et al
    NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis.
    Hepatology. 2024 Feb 5. doi: 10.1097/HEP.0000000000000767.
    PubMed     Abstract available


    January 2024
  33. CHOI WM, Yip TC, Kim WR, Yee LJ, et al
    Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
    Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752.
    PubMed     Abstract available



  34. Erratum: Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
    Hepatology. 2024 Jan 19. doi: 10.1097/HEP.0000000000000759.
    PubMed    


  35. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    PubMed     Abstract available


  36. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    PubMed     Abstract available


    December 2023
  37. KINAST V, Todt D
    The relation of host genetics and symptomatic hepatitis E.
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000749.
    PubMed    


  38. JENG WJ, Chien RN, Liaw YF
    Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737.
    PubMed    


  39. CHEN J, Tu T, Cohen C, Wang S, et al
    Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?
    Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732.
    PubMed    


  40. YIP TC, Brunetto MR
    Hepatitis B surface antigen seroclearance is uncommon but durable in the long run.
    Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000741.
    PubMed    


  41. SAADAT A, Gouttenoire J, Ripellino P, Semela D, et al
    Inborn errors of type I interferon immunity in patients with symptomatic acute hepatitis E.
    Hepatology. 2023 Dec 8. doi: 10.1097/HEP.0000000000000701.
    PubMed     Abstract available


    November 2023
  42. SHEN J, Zhang K, Liu M, Wang T, et al
    Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000682.
    PubMed    


  43. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    PubMed     Abstract available


  44. GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al
    Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687.
    PubMed     Abstract available


  45. HE S, Peng Y, Wei Q
    Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
    PubMed    


  46. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
    Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
    PubMed    


  47. DE CARVALHO RIBEIRO M, Babuta M, Szabo G
    Reply: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
    Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000686.
    PubMed    


  48. BRUDEN D, McMahon BJ, Snowball M, Towshend-Bulson L, et al
    Rate and durability of clearance of hepatitis B surface antigen in Alaska Native persons with long-term hepatitis B virus infection: 1982-2019.
    Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000658.
    PubMed     Abstract available


  49. LEE CH, Mak LY, Tang EH, Lui DT, et al
    SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
    Hepatology. 2023;78:1569-1580.
    PubMed     Abstract available


    October 2023
  50. JENG WJ, Chien RN, Liaw YF
    Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662.
    PubMed    


  51. DENG R, Wang Z, Liu Y, Sun J, et al
    Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654.
    PubMed    


  52. GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al
    Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis.
    Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642.
    PubMed     Abstract available


  53. DONGELMANS EJ, Sonneveld MJ, Janssen HLA
    Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639.
    PubMed    


  54. LIAW YF, Jeng WJ, Chien RN
    Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding?
    Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641.
    PubMed    


  55. ELSHEIKH R, Makram AM, Huy NT
    Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000625.
    PubMed    


  56. JAGADISAN B, Dhawan A
    Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000622.
    PubMed    


    September 2023
  57. CHOLANKERIL G, Vierling JM
    The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough!
    Hepatology. 2023 Sep 18. doi: 10.1097/HEP.0000000000000597.
    PubMed    


  58. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
    Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
    Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
    PubMed     Abstract available


  59. GILL US, Peppa D
    Pegylated interferon-alpha for chronic hepatitis B...not ready to be shelved yet! new insights on its role using single-cell transcriptomics.
    Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000560.
    PubMed     Abstract available


    August 2023
  60. JENG WJ, Chien RN, Chen YC, Lin CL, et al
    Hepatocellular carcinoma reduced, HBsAg loss increased and survival improved after finite therapy in hepatitis B patients with cirrhosis.
    Hepatology. 2023 Aug 25. doi: 10.1097/HEP.0000000000000575.
    PubMed     Abstract available


  61. CHANG X, Lv C, Wang B, Wang J, et al
    The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.
    Hepatology. 2023 Aug 23. doi: 10.1097/HEP.0000000000000563.
    PubMed     Abstract available


  62. JIANPING D, Xi C, Guangwen C, Fankun M, et al
    Dual elastography to discriminate adjacent stages of fibrosis and inflammation in chronic hepatitis B: A prospective multicenter study.
    Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000566.
    PubMed     Abstract available


  63. LI Y, Wen C, Gu S, Wang W, et al
    Differential response of HBV envelope-specific CD4 + T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy.
    Hepatology. 2023;78:592-606.
    PubMed     Abstract available


    July 2023
  64. MA X, Ding WX
    Reply: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000541.
    PubMed    


  65. HU X, Shen J, Wang T, Liu M, et al
    Letter to the Editor: Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitichondria and mitochondrial maladaptation.
    Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000540.
    PubMed    


  66. CABRE N, Hartmann P, Llorente C, Kouno T, et al
    IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice.
    Hepatology. 2023;78:295-306.
    PubMed     Abstract available


  67. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    PubMed     Abstract available


    June 2023
  68. JENG WJ, Liaw YF
    Letter to the Editor: Proper monitoring instead of expanding treatment for improving prognosis of indeterminate phase hepatitis B patients.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000526.
    PubMed    


  69. HUANG DQ, Nguyen MH
    Reply: Proper monitoring instead of expanding treatment for improving prognosis of indeterminate phase hepatitis B patients.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000525.
    PubMed    


  70. JIANG P, Jia H, Qian X, Tang T, et al
    Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-alpha in patients with chronic hepatitis B.
    Hepatology. 2023 Jun 27. doi: 10.1097/HEP.0000000000000524.
    PubMed     Abstract available


  71. GHANY MG, Buti M, Lampertico P, Lee HM, et al
    Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D- Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference.
    Hepatology. 2023 Jun 21. doi: 10.1097/HEP.0000000000000431.
    PubMed     Abstract available


  72. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    PubMed     Abstract available


  73. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    PubMed    


  74. DA BL
    Clinical trials in hepatitis D virus: Measuring success.
    Hepatology. 2023;77:2147-2157.
    PubMed     Abstract available


    May 2023
  75. LOK J, Dusheiko G
    Editorial: Re-assessing antiviral treatment criteria for chronic hepatitis B.
    Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000496.
    PubMed    


  76. TONON M, Balcar L, Semmler G, Calvino V, et al
    Etiological cure prevents further decompensation and mortality in cirrhotic patients with ascites as the single first decompensating event.
    Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460.
    PubMed     Abstract available


  77. HUANG DQ, Tran A, Yeh ML, Yasuda S, et al
    Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase.
    Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459.
    PubMed     Abstract available


  78. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    PubMed    


  79. GENSHAFT AS, Subudhi S, Keo A, Sanchez Vasquez JD, et al
    Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients.
    Hepatology. 2023 May 10. doi: 10.1097/HEP.0000000000000438.
    PubMed     Abstract available


  80. NG CH, Chan KE, Muthiah M, Tan C, et al
    Examining the interim proposal for name change to steatotic liver disease in the US population.
    Hepatology. 2023;77:1712-1721.
    PubMed     Abstract available


  81. HOWELL J, Seaman C, Wallace J, Xiao Y, et al
    Pathway to global elimination of hepatitis B: HBV cure is just the first step.
    Hepatology. 2023 May 1. doi: 10.1097/HEP.0000000000000430.
    PubMed     Abstract available


    April 2023
  82. KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al
    Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
    Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428.
    PubMed     Abstract available


  83. SONNEVELD MJ, Brouwer WP, Janssen HLA
    Treatment of diabetes mellitus in patients with chronic hepatitis B: Are SGLT2 inhibitors hitting the sweet spot?
    Hepatology. 2023 Apr 27. doi: 10.1097/HEP.0000000000000424.
    PubMed    


  84. GHANY MG, King WC, Hinerman AS, Lok AS, et al
    Use of HBV RNA and hepatitis B core-related antigen to predict change in serological status and disease activity in CHB.
    Hepatology. 2023 Apr 20. doi: 10.1097/HEP.0000000000000413.
    PubMed     Abstract available


  85. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    PubMed    


  86. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available


  87. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available


  88. CHAO X, Wang S, Ma X, Zhang C, et al
    Persistent mTORC1 activation due to loss of liver tuberous sclerosis complex 1 promotes liver injury in alcoholic hepatitis.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000373.
    PubMed     Abstract available


  89. STEINMANN S, Lohse AW
    Treatment of autoimmune hepatitis: Budesonide does not solve our problems.
    Hepatology. 2023;77:1071-1073.
    PubMed    


  90. TAN DJH, Setiawan VW, Ng CH, Lim WH, et al
    Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH.
    Hepatology. 2023;77:1150-1163.
    PubMed     Abstract available


    March 2023
  91. MAK LY, Yuen MF, Seto WK
    Reply: hepatic steatosis and glycemic burden in chronic hepatitis b.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000374.
    PubMed    


  92. HUANG SC, Kao JH
    Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B.
    Hepatology. 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
    PubMed    


  93. DE CARVALHO RIBEIRO M, Iracheta-Vellve A, Babuta M, Calenda CD, et al
    Alcohol-induced extracellular asc specks perpetuate liver inflammation and damage in alcoholic hepatitis even after alcohol cessation.
    Hepatology. 2023 Mar 3. doi: 10.1097/HEP.0000000000000298.
    PubMed     Abstract available


  94. WU X, Fan X, McMullen MR, Miyata T, et al
    Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis.
    Hepatology. 2023;77:902-919.
    PubMed     Abstract available


  95. LEGGIO L, Mellinger JL
    Alcohol use disorder in community management of chronic liver diseases.
    Hepatology. 2023;77:1006-1021.
    PubMed     Abstract available


    February 2023
  96. SZABO G, Mitchell M, Dasarathy S, McClain C, et al
    Reply: Survival in placebo-treated patients with severe alcoholic hepatitis".
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000337.
    PubMed    


  97. VAN MELKEBEKE L, Pollentier L, Van der Merwe S, Nevens F, et al
    Letter to the editor: survival in placebo-treated patients with severe alcoholic hepatitis.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000336.
    PubMed    



  98. Sociodemographic and geographic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis: Erratum.
    Hepatology. 2023 Feb 21. doi: 10.1097/HEP.0000000000000348.
    PubMed    


  99. ETZION O, Hamid S, Lurie Y, Gane EJ, et al
    Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000309.
    PubMed     Abstract available


  100. SCHRADER JA, Burkard TL, Bruggemann Y, Gomer A, et al
    Epidermal growth factor receptor modulates hepatitis e virus entry in human hepatocytes -HEP-22-1113.
    Hepatology. 2023 Feb 7. doi: 10.1097/HEP.0000000000000308.
    PubMed     Abstract available


  101. ABDUL MAJEED N, Zehnder B, Koh C, Heller T, et al
    Hepatitis delta: epidemiology to recent advances in therapeutic agents.
    Hepatology. 2023 Feb 6. doi: 10.1097/HEP.0000000000000331.
    PubMed    


  102. LUO W, Zhang Y, Zhang T
    Letter to the editor: Successful treatment of multidrug-resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2023;77:E26-E27.
    PubMed    


  103. LISKER-MELMAN M, Wahed AS, Ghany MG, Chung RT, et al
    HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
    Hepatology. 2023;77:594-605.
    PubMed     Abstract available


    January 2023
  104. HSU CC, Dodge JL, Weinberg E, Im G, et al
    Multi-Centered study of patient outcomes after declined for early liver transplantation in severe Alcohol-associated hepatitis.
    Hepatology. 2023 Jan 19. doi: 10.1097/HEP.0000000000000267.
    PubMed     Abstract available


  105. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available


  106. CUNNINGHAM M, Gupta R, Butler M
    Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045.
    PubMed     Abstract available


  107. DIAZ-GONZALEZ A, Hernandez-Guerra M, Perez-Medrano I, Sapena V, et al
    Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predni(so)lone administration.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000018.
    PubMed     Abstract available


  108. WU J, Kim A, Wu X, Ray S, et al
    5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000024.
    PubMed     Abstract available


    October 2022
  109. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    PubMed     Abstract available


    September 2022
  110. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.
    PubMed    


  111. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    PubMed     Abstract available


  112. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
    PubMed    


  113. YING D, He Q, Tian W, Chen Y, et al
    Urine Is a Viral Antigen Reservoir in Hepatitis E Virus Infection.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32745.
    PubMed     Abstract available


  114. MAO X, Cheung KS, Peng C, Mak LY, et al
    Steatosis, HBV-related hepatocellular carcinoma, cirrhosis & HBsAg seroclearance: a systematic review and meta-analysis.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32792.
    PubMed     Abstract available


  115. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    PubMed     Abstract available


  116. PAL S, Dey D, Chakraborty BC, Nandi M, et al
    Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
    Hepatology. 2022;76:759-774.
    PubMed     Abstract available


    August 2022
  117. LEE HM, Lidofsky SD, Taddei TH, Townshend-Bulson LJ, et al
    Attacking the Public Health Crisis of Hepatocellular Carcinoma at its Roots.
    Hepatology. 2022 Aug 21. doi: 10.1002/hep.32741.
    PubMed    


  118. SERPER M, Kaplan DE, Taddei TH, Tapper EB, et al
    Non-selective Beta Blockers, Hepatic Decompensation and Mortality in Cirrhosis: A National Cohort Study.
    Hepatology. 2022 Aug 19. doi: 10.1002/hep.32737.
    PubMed     Abstract available


  119. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    PubMed     Abstract available


  120. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    PubMed     Abstract available


    July 2022
  121. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.
    PubMed    


  122. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.
    PubMed    


  123. NASSAL M
    How many steps to a feasible mouse model of hepatitis B virus infection?
    Hepatology. 2022 Jul 24. doi: 10.1002/hep.32684.
    PubMed    


  124. ELSHEIKH R, Tien HT, Makram AM, Van NT, et al
    Acute Hepatitis of Unknown Origin in Children: Behind the Statistics.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32682.
    PubMed     Abstract available


  125. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.
    PubMed    


  126. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.
    PubMed    


  127. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    PubMed     Abstract available


  128. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    PubMed     Abstract available


  129. WU CR, Kim HJ, Sun CP, Chung CY, et al
    Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants.
    Hepatology. 2022;76:207-219.
    PubMed     Abstract available


  130. SINGH SP, Mishra AK, Jindal A
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.
    PubMed    


  131. GUPTA S, Nath P, Anand AC
    Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.
    PubMed    


    June 2022
  132. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    PubMed     Abstract available


  133. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed     Abstract available


  134. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    PubMed     Abstract available


  135. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    PubMed     Abstract available


  136. AHMAD A
    Letter to the Editor: Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32607.
    PubMed     Abstract available


  137. AHMAD A, Chaudhry HUR
    Letter to the Editor: Outcomes of pregnancy in autoimmune hepatitis: A population-based study.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32600.
    PubMed    


  138. WANG CY, Deng Y, Li P, Zheng S, et al
    Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;75:1373-1385.
    PubMed     Abstract available


    May 2022
  139. HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
    Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
    Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
    PubMed     Abstract available


  140. CHUNG Y, Heneghan MA
    Reply to: Medical therapy of autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32579.
    PubMed    


  141. EFE C, Purnak T
    Medical therapy of Autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 18. doi: 10.1002/hep.32576.
    PubMed    


  142. EFE C, Kulkarni AV, Beretta-Piccoli BT, Magro B, et al
    Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32572.
    PubMed     Abstract available


  143. NEUMANN-HAEFELIN C, Thimme R
    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.
    PubMed    


  144. MULCAHY VL, Mells GF
    Commentary on Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 May 2. doi: 10.1002/hep.32547.
    PubMed    


  145. PAPATHEODORIDI M, Tampaki M, Lok AS, Papatheodoridis GV, et al
    Risk of HBV reactivation during therapies for HCC: A systematic review.
    Hepatology. 2022;75:1257-1274.
    PubMed     Abstract available


    April 2022
  146. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.
    PubMed    


  147. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    PubMed     Abstract available


  148. LUCEY MR, Thursz M
    We need a new approach to clinical trials in alcohol-associated hepatitis. Is there a lesson in RECOVERY?
    Hepatology. 2022 Apr 13. doi: 10.1002/hep.32523.
    PubMed    


  149. COFFIN CS
    The remarkable success of the vaccine for a killer virus: Hepatitis B.
    Hepatology. 2022 Apr 11. doi: 10.1002/hep.32346.
    PubMed    


  150. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available


  151. WAT C, Gane E, Yuen MF, Pavlovic V, et al
    Reply.
    Hepatology. 2022;75:1050-1051.
    PubMed    


    March 2022
  152. SUNDARAM V, Jalan R
    Letter to the editor: the role of acute-on-chronic liver failure in predicting recovery in severe alcoholic hepatitis.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32495.
    PubMed    


  153. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    PubMed     Abstract available


  154. SZABO G, Mitchell M, McClain CJ, Dasarathy S, et al
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32478.
    PubMed     Abstract available


  155. BRUCE MG, Bruden D, Hurlburt D, Morris J, et al
    Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32474.
    PubMed     Abstract available


  156. LOUKACHOV V, van Dort K, Erken R, Reesink HW, et al
    Reponse to: Letter to the Editor concerning Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32472.
    PubMed    


  157. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    PubMed     Abstract available


  158. HE Q, Zhang F, Shu J, Li S, et al
    Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
    PubMed     Abstract available


  159. HOWELL J, Hellard M
    Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32450.
    PubMed    


  160. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.
    PubMed    


  161. KANWAL F, Khaderi S, Singal AG, Marrero JA, et al
    Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434.
    PubMed     Abstract available


    February 2022
  162. PATWA AK, Rungta S, Kumar V
    Nanoparticle therapeutic vaccine for hepatitis B: an unfulfilled dream.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32421.
    PubMed    


  163. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.
    PubMed    


  164. ZHANG J, Zhao T, Wei L, Wu Y, et al
    Reply: epsilonPA-44 may expand the arsenal for chronic hepatitis B combination treatment towards functional cure.
    Hepatology. 2022 Feb 24. doi: 10.1002/hep.32423.
    PubMed    


  165. PERRILLO RP, Lin HS, Schwarz KB, Rosenthal P, et al
    Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.
    Hepatology. 2022 Feb 21. doi: 10.1002/hep.32400.
    PubMed     Abstract available


  166. LI Y, Sun Y, Liu Y, Wang B, et al
    Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32417.
    PubMed     Abstract available


  167. CHUNG YY, Heneghan MA
    Autoimmune hepatitis in pregnancy: pearls and pitfalls.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32410.
    PubMed     Abstract available


  168. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available


  169. TU T, Zhang H
    Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32388.
    PubMed    


  170. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available


  171. WANG X, Wei Z, Cheng B, Li J, et al
    Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis.
    Hepatology. 2022;75:438-454.
    PubMed     Abstract available


    January 2022
  172. HUANG V, Lewin C, Novy P
    Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the US.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32376.
    PubMed    


  173. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available


  174. PAN CQ, Jacobson IM, Martin P, Kwo P, et al
    Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
    Hepatology. 2022 Jan 28. doi: 10.1002/hep.32366.
    PubMed    


  175. ERKEN R, Loukachov V, van Dort K, van den Hurk A, et al
    Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32352.
    PubMed     Abstract available


  176. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    PubMed     Abstract available


  177. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    PubMed     Abstract available


  178. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available


  179. PAN JJ, Razumilava N
    Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: is less more?
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32330.
    PubMed    


  180. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.
    PubMed    


  181. JINDAL A
    Oral antivirals in treatment naive chronic hepatitis C infection.
    Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.
    PubMed    


  182. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    PubMed     Abstract available


    December 2021
  183. COHEN C, Moraras K, Jackson M, Kamischke M, et al
    Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32304.
    PubMed    


  184. CHEN VL, Ramrakhiani NS, Nguyen MH
    Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32303.
    PubMed    


  185. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
    A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
    Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
    PubMed     Abstract available


  186. SUZUKI Y, Kakisaka K, Takikawa Y
    Letter to the Editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population based-epidemiological study.
    Hepatology. 2021 Dec 13. doi: 10.1002/hep.32280.
    PubMed    


  187. MUSTO J, Lucey MR, Rice J
    Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32275.
    PubMed    


  188. JINDAL A
    Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32276.
    PubMed    


  189. WEI L, Ploss A
    Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles.
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32273.
    PubMed    


  190. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.
    PubMed    


  191. CAO Z, Gui H, Sheng Z, Xin H, et al
    Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32269.
    PubMed     Abstract available


  192. YURDAYDIN C, Keskin O, Yurdcu E, Caliskan A, et al
    A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32259.
    PubMed     Abstract available


  193. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
    Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
    PubMed     Abstract available


  194. HE WQ, Guo GN, Li C
    The impact of hepatitis B vaccination in United States, 1999-2018.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32265.
    PubMed     Abstract available


  195. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
    A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
    Hepatology. 2021;74:2974-2987.
    PubMed     Abstract available


  196. ISNARD P, Larue M, Pitsch A, Duong Van Huyen JP, et al
    A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease.
    Hepatology. 2021;74:3549-3551.
    PubMed    


    November 2021
  197. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32248.
    PubMed     Abstract available


  198. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32249.
    PubMed     Abstract available


  199. WANG Y, Li Y, Zai W, Hu K, et al
    Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32245.
    PubMed     Abstract available


  200. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    PubMed     Abstract available


  201. TABERNERO D, Cortese MF, Rando-Segura A, Buti M, et al
    Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32227.
    PubMed     Abstract available


  202. TERRAULT NA, Wahed AS, Feld JJ, Cooper SL, et al
    Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32231.
    PubMed     Abstract available


  203. KUIPERY A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, et al
    Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32230.
    PubMed     Abstract available


  204. ROY A, Dhiman RK
    Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Hepatology. 2021;74:2909.
    PubMed    


  205. GHANY MG, King WC, Lisker-Melman M, Lok ASF, et al
    Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
    Hepatology. 2021;74:2395-2409.
    PubMed     Abstract available


  206. SHEN Y, Cingolani F, Malik SA, Wen J, et al
    Sex-Specific Regulation of Interferon-gamma Cytotoxicity in Mouse Liver by Autophagy.
    Hepatology. 2021;74:2745-2758.
    PubMed     Abstract available


  207. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available


  208. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
    Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
    Hepatology. 2021;74:2714-2724.
    PubMed     Abstract available


    October 2021
  209. BEKKI Y, Fenig Y
    Outcomes of Severe Alcohol-Related Hepatitis with or without Early Liver Transplantation.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32219.
    PubMed     Abstract available


  210. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    PubMed     Abstract available


  211. KHANAM A, Kottilil S, Tang LSY
    PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Oct 24. doi: 10.1002/hep.32210.
    PubMed     Abstract available


  212. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
    Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
    PubMed     Abstract available


  213. HU K, Camila Perez-Matos M, Argemi J, Vilar E, et al
    Lipoprotein Z, A novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32203.
    PubMed     Abstract available


  214. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available


  215. KUSHNER T, Chappell CA
    Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
    Hepatology. 2021;74:2311-2312.
    PubMed    


  216. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available


    September 2021
  217. YASSEEN AS, Kwong JC, Feld JJ, Kustra R, et al
    The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
    Hepatology. 2021 Sep 19. doi: 10.1002/hep.32162.
    PubMed     Abstract available


  218. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32156.
    PubMed     Abstract available


  219. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    PubMed     Abstract available


  220. RAMRAKHIANI NS, Chen VL, Le M, Yeo YH, et al
    Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32142.
    PubMed     Abstract available


  221. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    PubMed     Abstract available


  222. TAUBERT R, Engel B, Diestelhorst J, Hupa-Breier KL, et al
    Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32134.
    PubMed     Abstract available


  223. DING WB, Wang MC, Yu J, Huang G, et al
    HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
    Hepatology. 2021;74:1480-1495.
    PubMed     Abstract available


  224. STERLING RK, King WC, Khalili M, Chung RT, et al
    A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
    Hepatology. 2021;74:1174-1189.
    PubMed     Abstract available


  225. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
    Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
    Hepatology. 2021;74:1148-1163.
    PubMed     Abstract available


    August 2021
  226. WANG CW, Grab J, Tana MM, Irani RA, et al
    Outcomes of Pregnancy in Autoimmune Hepatitis: A Population-Based Study.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32132.
    PubMed     Abstract available


  227. WEI L, Zhao T, Zhang J, Mao Q, et al
    Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32109.
    PubMed     Abstract available


  228. LI Y, Yu P, Kessler AL, Shu J, et al
    Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32114.
    PubMed     Abstract available


  229. YIP TC, Wong VW, Wong GL
    Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32116.
    PubMed     Abstract available


  230. JINDAL A
    Outcomes in chronic hepatitis B infection and COVID-19 - Not always benign !
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32108.
    PubMed     Abstract available


  231. OECHSLIN N, Da Silva N, Szkolnicka D, Cantrelle FX, et al
    Hepatitis E Virus RNA-Dependent RNA Polymerase is Involved in RNA Replication and Infectious Particle Production.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32100.
    PubMed     Abstract available


  232. LV XH, Yang JL, Deng K
    Letter to the Editor: unanswered questions about hepatitis B virus infection in patients with COVID-19.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32098.
    PubMed     Abstract available


  233. MUSTO J, Stanfield D, Ley D, Lucey MR, et al
    Recovery and Outcomes of Patients Denied Early Liver Transplantation (LT) for Severe Alcohol-Related Hepatitis (AH).
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32110.
    PubMed     Abstract available


  234. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    PubMed     Abstract available


  235. TOYODA H, Leong J, Landis C, Atsukawa M, et al
    Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
    Hepatology. 2021;74:656-666.
    PubMed     Abstract available


  236. LIANG YJ, Teng W, Chen CL, Sun CP, et al
    Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Hepatology. 2021;74:641-655.
    PubMed     Abstract available


    July 2021
  237. LOK AS, Negro F, Asselah T, Farci P, et al
    Endpoints and new options for treatment of chronic hepatitis D.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32082.
    PubMed     Abstract available


  238. CHOLANKERIL G, Goli K, Rana A, Hernaez R, et al
    Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32067.
    PubMed     Abstract available


  239. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available


  240. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    PubMed     Abstract available


  241. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available


  242. CHO Y, Szabo G
    Two Faces of Neutrophils in Liver Disease Development and Progression.
    Hepatology. 2021;74:503-512.
    PubMed     Abstract available


    June 2021
  243. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed     Abstract available


  244. BEUDEKER BJB, Janssen HLA, Boonstra A
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
    PubMed     Abstract available


  245. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
    PubMed     Abstract available


  246. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed     Abstract available


  247. ROBERTS H, Ly KN, Yin S, Hughes E, et al
    Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
    PubMed     Abstract available


  248. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
    Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
    PubMed     Abstract available


  249. CHOI J, Yoo S, Lim YS
    Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Hepatology. 2021;73:2155-2166.
    PubMed     Abstract available


    May 2021
  250. GANE E, Yuen MF, Kim DJ, Chan HL, et al
    Clinical Study of Single Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31920.
    PubMed     Abstract available


  251. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    PubMed     Abstract available


  252. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    PubMed     Abstract available


  253. RIEDL T, Faure-Dupuy S, Rolland M, Schuehle S, et al
    HIF1alpha-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
    Hepatology. 2021 May 15. doi: 10.1002/hep.31902.
    PubMed     Abstract available


  254. YIP TC, Wong VW, Lui GC, Chow VC, et al
    Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19.
    Hepatology. 2021 May 7. doi: 10.1002/hep.31890.
    PubMed     Abstract available


  255. LIAO H, Wang J, Liu Y, Chen J, et al
    Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
    Hepatology. 2021;73:2075-2076.
    PubMed    


  256. BRUNT EM, Kleiner DE, Carpenter DH, Rinella M, et al
    NAFLD: Reporting Histologic Findings in Clinical Practice.
    Hepatology. 2021;73:2028-2038.
    PubMed     Abstract available


    April 2021
  257. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available


  258. LIU Y, Wang S, Hu L
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31842.
    PubMed     Abstract available


  259. LEE YB, Lee J
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B - The Authors' reply.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31844.
    PubMed     Abstract available


  260. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    PubMed     Abstract available


  261. ABUTALEB A, Khatun M, Clement J, Baidya A, et al
    A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.
    Hepatology. 2021;73:1261-1274.
    PubMed     Abstract available


    February 2021
  262. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available


  263. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.
    PubMed    


  264. KIM GW, Imam H, Khan M, Mir SA, et al
    HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.
    Hepatology. 2021;73:533-547.
    PubMed     Abstract available


  265. CHEN J, Li Y, Lai F, Wang Y, et al
    Functional Comparison of Interferon-alpha Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-alpha and Interferon-gamma Signaling.
    Hepatology. 2021;73:486-502.
    PubMed     Abstract available


  266. ZHAO X, Fan H, Chen X, Zhao X, et al
    Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.
    Hepatology. 2021;73:503-519.
    PubMed     Abstract available


    November 2020
  267. HAFEZI M, Lin M, Chia A, Chua A, et al
    Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31662.
    PubMed     Abstract available


  268. BERTOLETTI A
    ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection.
    Hepatology. 2020;72:1514-1517.
    PubMed    


    September 2020
  269. ZHAO Q, Guo JT
    Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
    Hepatology. 2020;72:1142-1144.
    PubMed    


    August 2020
  270. KAPILA N, Rahman AU, Zervos XB
    Reply.
    Hepatology. 2020;72:788.
    PubMed    


    July 2020
  271. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available


  272. CRESCI GAM
    Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?
    Hepatology. 2020;72:4-6.
    PubMed    


    April 2020
  273. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available


  274. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available


  275. YANG Y, Zhao X, Wang Z, Shu W, et al
    Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
    Hepatology. 2020;71:1154-1169.
    PubMed     Abstract available


    March 2020
  276. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
    HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
    PubMed     Abstract available


  277. ZENG J, Wu D, Hu H, Young JAT, et al
    Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
    PubMed     Abstract available


    December 2019
  278. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available


    October 2019
  279. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available


    September 2019
  280. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    PubMed     Abstract available


  281. DONG B, Zhou Y, Wang W, Scott J, et al
    Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
    PubMed     Abstract available


    August 2019
  282. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available


  283. ZHOU Y, Dong B, Kim KH, Choi S, et al
    Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
    Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.